Familial melanoma - Associated mutations in p16 uncouple its tumor-suppressor functions

Journal of Investigative Dermatology

Volumn 133, Issue 4, 2013, Pages 1043-1051

  Jenkins, Noah C ^a,b   Jung, Jae ^c   Liu, Tong ^b   Wilde, Megan ^b   Holmen, Sheri L ^a,b   Grossman, Douglas ^a,b,c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; PROTEIN P16; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL CYCLE; CELL FUNCTION; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MELANOMA; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

EID: 84875217967     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.401     Document Type: Article

References (48)

1. Alcorta DA, Xiong Y, Phelps D et al. (1996) Involvement of the cyclindependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93:13742-7
2. Bae I, Fan S, Meng Q et al. (2004) BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 64:7893-909
3. Bartkova J, Lukas J, Guldberg P et al. (1996) The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-83
4. Becker TM, Ayub AL, Kefford RF et al. (2005) The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired. Int J Cancer 117:569-73
5. Becker TM, Rizos H, Kefford RF et al. (2001) Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding. Clin Cancer Res 7:3282-8
6. Bishop DT, Demenais F, Goldstein AM et al. (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894-903
7. Bragado P, Armesilla A, Silva A et al. (2007) Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 12:1733-42
8. Byeon IJ, Li J, Ericson K et al. (1998) Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclindependent kinase 4. Mol Cell 1:421-31
9. Chen W, Sun Z, Wang XJ et al. (2009) Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34:663-73
10. Cotter MA, Florell SR, Leachman SA et al. (2007) Absence of senescenceassociated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol 127:2469-71
11. Evangelou K, Bramis J, Peros I et al. (2004) Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) ''nuclear'' cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem 79:5-10
12. Fahraeus R, Paramio JM, Ball KL et al. (1996) Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 6:84-91
13. Goldstein AM, Chan M, Harland M et al. (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99-106
14. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714-3
15. Hashemi J, Platz A, Ueno T et al. (2000) CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 60:6864-7
16. Herrling T, Jung K, Fuchs J (2006) Measurements of UV-generated free radicals/reactive oxygen species (ROS) in skin. Spectrochim Acta A Mol Biomol Spectrosc 63:840-5
17. Hirai H, Roussel MF, Kato JY et al. (1995) Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672-81
18. Jenkins NC, Liu T, Cassidy P et al. (2011) The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene 30:265-74
19. Jones R, Ruas M, Gregory F et al. (2007) A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6. Cancer Res 67:9134-41
20. Kamijo T, Zindy F, Roussel MF et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-59
21. Kannengiesser C, Brookes S, del Arroyo AG et al. (2009) Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. Hum Mutat 30:564-74
22. Koh J, Enders GH, Dynlacht BD et al. (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-10
23. Le Page F, Randrianarison V, Marot D et al. (2000) BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 60:5548-2
24. Li J, Byeon IJ, Ericson K et al. (1999) Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A. Biochemistry 38:2930-40
25. Li J, Mahajan A, Tsai MD (2006) Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 45:15168-78
26. Lukas J, Parry D, Aagaard L et al. (1995) Retinoblastoma-protein- dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503-6
27. Macip S, Igarashi M, Berggren P et al. (2003) Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol 23:8576-85
28. Macip S, Igarashi M, Fang L et al. (2002) Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 21:2180-8
29. Mahajan A, Guo Y, Yuan C et al. (2007) Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16. J Mol Biol 373:990-1005
30. McKenzie HA, Fung C, Becker TM et al. (2010) Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Hum Mutat 31:692-701
31. Miller PJ, Duraisamy S, Newell JA et al. (2011) Classifying variants of CDKN2A using computational and laboratory studies. Hum Mutat 32:900-11
32. Nishiwaki E, Turner SL, Harju S et al. (2000) Regulation of CDK7-carboxylterminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation. Mol Cell Biol 20:7726-34
33. Parry D, Peters G (1996) Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16:3844-52
34. Polyak K, Xia Y, Zweier JL et al. (1997) A model for p53-induced apoptosis. Nature 389:300-5
35. Raj D, Liu T, Samadashwily G et al. (2008) Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29:194-201
36. Ranade K, Hussussian CJ, Sikorski RS et al. (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114-6
37. Reymond A, Brent R (1995) p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 11:1173-8
38. Russo AA, Tong L, Lee JO et al. (1998) Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395:237-43
39. Serizawa H (1998) Cyclin-dependent kinase inhibitor p16INK4A inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH. J Biol Chem 273:5427-30
40. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-7
41. Shapiro GI, Edwards CD, Ewen ME et al. (1998) p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18:378-87
42. Sharpless NE, DePinho RA (1999) The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 9:22-30
43. Takahashi A, Ohtani N, Yamakoshi K et al. (2006) Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 8:1291-7
44. Tevelev A, Byeon IJ, Selby T et al. (1996) Tumor suppressor p16INK4A: structural characterization of wild-type and mutant proteins by NMR and circular dichroism. Biochemistry 35:9475-87
45. Vurusaner B, Poli G, Basaga H (2012) Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med 52:7-18
46. Walker GJ, Hussussian CJ, Flores JF et al. (1995) Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 4:1845-52
47. Welm BE, Dijkgraaf GJ, Bledau AS et al. (2008) Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell 2:90-102
48. Yang R, Gombart AF, Serrano M et al. (1995) Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res 55:2503-6